2. Search Result
Search Result
Results for "

BSO

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

1

MCE Kits

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-106376
    DL-Buthionine-(S,R)-sulfoximine
    Maximum Cited Publications
    16 Publications Verification

    Buthionine sulfoximine; BSO

    		 Ferroptosis Cancer
    DL-Buthionine-(S,R)-sulfoximine is a potent inhibitor of glutamylcysteine synthetase biosynthesis.
    DL-Buthionine-(S,R)-sulfoximine
  • HY-106376B
    DL-Buthionine-(S,R)-sulfoximine hydrochloride
    Maximum Cited Publications
    16 Publications Verification

    Buthionine sulfoximine hydrochloride; BSO hydrochloride

    		 Ferroptosis Cancer
    DL-Buthionine-(S,R)-sulfoximine hydrochloride (Buthionine sulfoximine hydrochloride) is a potent inhibitor of glutamylcysteine synthetase biosynthesis.
    DL-Buthionine-(S,R)-sulfoximine hydrochloride
  • HY-106376A
    L-Buthionine-(S,R)-sulfoximine
    5+ Cited Publications

    L-Buthionine sulfoximine; L-BSO

    		 Ferroptosis Cancer
    L-Buthionine-(S,R)-sulfoximine is a cell-permeable, potent, fast acting and irreversible inhibitor of g-glutamylcysteine synthetase and depletes cellular glutathione levels. The IC50 value of L-Buthionine-(S,R)-sulfoximine on melanoma, breast and ovarian tumor specimens are 1.9 μM, 8.6 μM, and 29 μM, respectively.
    L-Buthionine-(S,R)-sulfoximine
  • HY-106376C
    L-Buthionine-(S,R)-sulfoximine hydrochloride
    5+ Cited Publications

    L-Buthionine sulfoximine hydrochloride; L-BSO hydrochloride

    		 Ferroptosis Metabolic Disease Cancer
    L-Buthionine-(S,R)-sulfoximine hydrochloride is a cell-permeable, potent, fast acting, orally active and irreversible inhibitor of g-glutamylcysteine synthetase and depletes cellular glutathione levels. The IC50 value of L-Buthionine-(S,R)-sulfoximine on melanoma, breast and ovarian tumor specimens are 1.9 μM, 8.6 μM, and 29 μM, respectively .
    L-Buthionine-(S,R)-sulfoximine hydrochloride
  • HY-162886
    BSO-07

    		JNK Reactive Oxygen Species Cancer
    BSO-07 is a ROS/JNK activator with significant anticancer effects, having an IC50 value of 24.81 μM against human breast cancer (BC) cells. BSO-07 induces apoptosis (Apoptosis) and paraptosis by activating JNK and increasing ROS levels, including enhancing the expression of apoptosis-associated proteins such as PARP, Bax, phosphorylated p53, ATF4, and CHOP, while decreasing the levels of anti-apoptotic proteins like Bcl-2, Bcl-xL, and Survivin. BSO-07 holds promise for research in the field of breast cancer .
    BSO-07
  • HY-158740
    1(R)-(Trifluoromethyl)oleyl alcohol

    		Ferroptosis Neurological Disease
    1(R)-(Trifluoromethyl)oleyl alcohol (compound (R)-24) is a trifluoromethyl alcohol derivative of Oleic acid (HY-N1446) with activity in multiple models of Friedreich ataxia (FRDA). 1(R)-(Trifluoromethyl)oleyl alcohol inhibits ferroptosis induced by Erastin (HY-15763) and decreases lipid peroxidation in NBT human myoblasts with frataxin (FXN) siRNA knockdown. 1(R)-(Trifluoromethyl)oleyl alcohol at 40 μM increases survival to 95% in a model of FRDA where a significant percentage of cell death is caused by FAC (HY-B1645) and BSO (HY-106376) .
    1(R)-(Trifluoromethyl)oleyl alcohol
  • HY-121648
    PK 130

    		Others Cancer
    PK 130 is a 2-nitroimidazole derivative that demonstrated potent hypoxic cellular radiosensitization in vitro as assessed by aerobic and hypoxic radiosensitivity of Chinese hamster V79 cells. PK 130 and PK 110 were more potent than SR-2508 at the same concentrations at 0.1 and 1.0 mM. The relative radiosensitization produced by PK 130 and PK 110 at 0.1 mM was comparable to that of 1.0 mM SR-2508. However, at 0.1 mM, the therapeutic effects of PK 130 and PK 110 were only modestly aerobic radiosensitizing. The relative radiosensitization of PK 130 and PK 110 at 0.1 mM was further enhanced by the reduction of glutathione (GSH) levels (less than 5% of control levels) by L-cysteine sulfoxide (BSO). The results of this study encourage the in vivo tumor radiosensitization evaluation of PK 130 and PK 110.
    PK 130

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: